+++
title = "LIBERTY-CSU CUPID A"
description = "Is Dupilumab an effective treatment for CSU refractory to high dose AH?"
date = 2025-10-29
draft = true

[taxonomies]
tags = ["Research","CSU"]
[extra]
keywords = "CSU, chronic spontaneous urticaria"
toc = true
authors = ["Joshua Yu"]
+++

<table style="margin:0rem">
  <tr>
    <td>
{% admonition(type="info", icon="info", title="Trial metadata") %}

- Published: 2024
- Journal: JACI
- Funded by: Sanofi, Regeneron

{% end %}

</td>
<td>

{% admonition(type="note", icon="info", title="Contributors") %}

<div class="contributor-group">
<i class="fas fa-pen-nib"></i>  Primary Author: Joshua Yu</div>
  <div class="contributor-group">
</div>
<i class="fas fa-user-edit"></i> Editor: TBD
  <div class="contributor-group">
<i class="fas fa-star"></i>  Staff Reviewer: TBD
</div>

{% end %}

</td>

</tr>
</table>

{{ research_card(paper="liberty_csu_cupid_a", show_title=true) }}

## What's the clinical question?

<span class="hl-yellow">In patients with mild asthma, is PRN budesonide-formoterol non-inferior to budesonide maintenance therapy in preventing severe asthma exacerbations?</span>

{% admonition(type="tip", icon="question", title="Why should we care?") %}

Blah

{% end %}

## PICO

{% two_columns_fancy() %}

**Population**:

- **Inclusion Criteria**:
- **Relevant Exclusion Criteria**:

<!-- split -->

**Intervention**:

**Comparison**:

**Outcome**:

- **Primary**:
- **Relevant Secondary**:

{% end %}

## Study Design

This study was a <span class="hl-yellow">double-blind, multicenter, parallel-group randomized controlled trial</span> conducted over <span class="hl-yellow">52 weeks</span> across 354 sites in 25 countries.

### How were outcomes assessed?

#### Primary

#### Secondary

### Statistical analysis

## Results

### Table 1: patients

<span class="hl-yellow">From each group, only about 1% of patients were lost to follow-up</span>.

### Primary Outcome

### Secondary Outcomes

#### Adverse Events

## Limitations

## Comparison to other biologics:

https://www.nejm.org/doi/full/10.1056/NEJMoa1215372

12 week endpoint
UAS7 baseline score 30ish
UAS7 <=6 19% placebo vs 300mg q4weekly 66%

https://www.sciencedirect.com/science/article/pii/S0091674925006463

## Risk of Bias 2 for primary outcome

Outcome: low risk
